JP2023544620A - 抗ｉｌ１２／ｉｌ２３抗体によるクローン病のための治療方法 - Google Patents

抗ｉｌ１２／ｉｌ２３抗体によるクローン病のための治療方法 Download PDF

Info

Publication number
JP2023544620A
JP2023544620A JP2023521437A JP2023521437A JP2023544620A JP 2023544620 A JP2023544620 A JP 2023544620A JP 2023521437 A JP2023521437 A JP 2023521437A JP 2023521437 A JP2023521437 A JP 2023521437A JP 2023544620 A JP2023544620 A JP 2023544620A
Authority
JP
Japan
Prior art keywords
antibody
subject
weeks
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544620A5 (https=
JPWO2022074603A5 (https=
Inventor
ラヴィ，フレデリック
バース，マニュエラ ル
プロトニック，マイケル
スローン，シェルドン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2023544620A publication Critical patent/JP2023544620A/ja
Publication of JP2023544620A5 publication Critical patent/JP2023544620A5/ja
Publication of JPWO2022074603A5 publication Critical patent/JPWO2022074603A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023521437A 2020-10-09 2021-10-07 抗ｉｌ１２／ｉｌ２３抗体によるクローン病のための治療方法 Pending JP2023544620A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063089786P 2020-10-09 2020-10-09
US63/089,786 2020-10-09
US202163235188P 2021-08-20 2021-08-20
US63/235,188 2021-08-20
PCT/IB2021/059211 WO2022074603A1 (en) 2020-10-09 2021-10-07 Method for treating crohn's disease with anti-il12/il23 antibody

Publications (3)

Publication Number Publication Date
JP2023544620A true JP2023544620A (ja) 2023-10-24
JP2023544620A5 JP2023544620A5 (https=) 2024-10-15
JPWO2022074603A5 JPWO2022074603A5 (https=) 2024-10-15

Family

ID=81078738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521437A Pending JP2023544620A (ja) 2020-10-09 2021-10-07 抗ｉｌ１２／ｉｌ２３抗体によるクローン病のための治療方法

Country Status (10)

Country Link
US (1) US20220112282A1 (https=)
EP (1) EP4225350A4 (https=)
JP (1) JP2023544620A (https=)
KR (1) KR20230084283A (https=)
CN (1) CN116348491A (https=)
AU (1) AU2021356282A1 (https=)
CA (1) CA3198413A1 (https=)
IL (1) IL301944A (https=)
MX (1) MX2023004017A (https=)
WO (1) WO2022074603A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471655B (zh) * 2020-03-19 2023-07-07 湖州正熙医学检验实验室有限公司 抗人il12/23稳转细胞株及其构建方法和应用
AU2024301395A1 (en) * 2023-07-21 2025-12-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of il-12 related biomarkers and il-12 specific blocking antibodies for the treatment of an autoimmune disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020128864A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020128864A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE NCT03107793 ON 2020_09_29, JPN6025048153, 29 September 2020 (2020-09-29), ISSN: 0005738133 *
CROHNS COLITIS 360, vol. 2(4), JPN6025048156, July 2020 (2020-07-01), pages 061 - 1, ISSN: 0005738134 *
GASTROENTEROLOGY, vol. 158(6), Supplement 1, JPN6025048155, May 2020 (2020-05-01), pages 1193 - 1194, ISSN: 0005738136 *
J. CROHNS COLITIS, vol. 13(7), JPN6025048154, 2019, pages 864 - 872, ISSN: 0005738135 *

Also Published As

Publication number Publication date
CN116348491A (zh) 2023-06-27
IL301944A (en) 2023-06-01
CA3198413A1 (en) 2022-04-14
EP4225350A4 (en) 2025-01-22
KR20230084283A (ko) 2023-06-12
EP4225350A1 (en) 2023-08-16
WO2022074603A1 (en) 2022-04-14
US20220112282A1 (en) 2022-04-14
AU2021356282A1 (en) 2023-06-15
MX2023004017A (es) 2023-07-05
AU2021356282A9 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
US12404324B2 (en) Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
JP2024088688A (ja) 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
CZ38255U1 (cs) Protilátka proti IL-12/IL-23p40 pro použití při způsobu léčení středně až závažně aktivní vředové kolitidy
JP2023025173A (ja) 抗ｉｌ２３特異的抗体で乾癬を治療する方法
JP2024038223A (ja) 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
US20240002494A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
KR20240103043A (ko) 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
JP2023544620A (ja) 抗ｉｌ１２／ｉｌ２３抗体によるクローン病のための治療方法
US20240101662A1 (en) Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
JP2025539830A (ja) 抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
US20200331996A1 (en) Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
US20240294625A1 (en) Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
KR20250011938A (ko) Il23 항체에 의해 건선성 관절염을 평가 및 치료하기 위한 방법
CN118401550A (zh) 用抗il23特异性抗体治疗溃疡性结肠炎的方法
EA051014B1 (ru) Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260421